treatment of CRPC
nanomedicine treatment Prostate cancer
CDx test
Prostate cancer extracellular vesicles
nanomedicine combination treatment
proposed treatment
prostate biopsies
number of EVs
castration-resistant prostate cancer
deadliest types of cancer
Prostate specific antigen
nanomedicine-based combination therapy
LNPs
cytotoxic anti-cancer agent docetaxel
synergistic therapeutic effects
standard biomarker measurements
possible biomarker candidates
Early stage PC
preclinical evaluation
therapeutic efficacy
co-development
liquid biopsies
application of PSA
free drug
flow cytometry-based immunodetection platforms
tumour-targeted nanomedicines
lethal end-stage disease
biomarkers
immunocapture
analysis
patients
microfluidics-prepared lipid nanoparticles
plasma levels
information
siRNAs
excitement
reliable companion diagnostic
urine samples
potential
parental cell
rational strategy
genes
fingerprint
blood
patient survival
males
cells
composition
intercellular communication
diagnosis
predictability issues
Advanced therapies
opportunities
bodily fluids
prognosis
aim